title: Vascular endothelial growth factor enhances cancer cell adhesion to microvascular endothelium in vivo.
abstract: To investigate whether vascular endothelial growth factor (VEGF) enhances cancer cell adhesion to normal microvessels, we used in vivo video microscopy to measure adhesion rates of MDA-MB-435s human breast cancer cells and ErbB2-transformed mouse mammary carcinomas in the postcapillary venules of rat mesentery. An individual postcapillary venule in the mesentery was injected via a glass micropipette with cancer cells either in a perfusate of mammalian Ringer solution containing 1% bovine serum albumin as a control, or with the addition of 1 nm VEGF for test measurements. Cell adhesion was measured as either the number of adherent cells or the fluorescence intensity of adherent cells in a vessel segment for 60 min. Our results showed that during both control and VEGF treatments, the number of adherent cells increased almost linearly with time over 60 min. The VEGF treatment increased the adhesion rates of human tumour cells and mouse carcinomas 1.9-fold and 1.8-fold, respectively, over those in control conditions. We also measured cancer cell adhesion after pretreatment of cells with an antibody blocking VEGF or an antibody blocking alpha 6 integrin, and pretreatment of the microvessel with VEGF receptor (KDR/Flk-1) inhibitor, SU1498, or anti-integrin extracellular matrix ligand antibody, anti-laminin-5. All antibodies and inhibitor significantly reduced adhesion, with anti-VEGF and SU1498 reducing it the most. Our results indicate that VEGF enhances cancer cell adhesion to the normal microvessel wall, and further suggest that VEGF and its receptor, KDR/Flk-1, as well as integrins of tumour cells and their ligands at the endothelium, contribute to mammary cancer cell adhesion to vascular endothelium in vivo.
authors.affiliation: Department of Mechanical Engineering, University of Nevada, Las Vegas, 4505 Maryland Parkway, Box 454027, Las Vegas, NV 89154, USA.
authors.forename: Shang
authors.initials: S
authors.lastname: Shen
authors.forename: Jie
authors.initials: J
authors.lastname: Fan
authors.forename: Bin
authors.initials: B
authors.lastname: Cai
authors.forename: Yonggang
authors.initials: Y
authors.lastname: Lv
authors.forename: Min
authors.initials: M
authors.lastname: Zeng
authors.forename: Yanyan
authors.initials: Y
authors.lastname: Hao
authors.forename: Filippo G
authors.initials: FG
authors.lastname: Giancotti
authors.forename: Bingmei M
authors.initials: BM
authors.lastname: Fu
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000503:physiopathology*; D002448:Cell Adhesion / Q000187:drug effects; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology*; D005260:Female; D006801:Humans; D051379:Mice; D051381:Rats; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage* / Q000378:metabolism*
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A